Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GILD Gilead Sciences	$125.59 -0.2%	$133.16	$104.46 ▼ $157.29	$156.28B	0.31	7.74 million shs	5.21 million shs
LLY Eli Lilly and Company	$1,137.01 -2.1%	$998.47	$623.78 ▼ $1,182.73	$1.09T	0.53	3.12 million shs	2.43 million shs
MDT Medtronic	$80.11 -0.3%	$80.85	$73.31 ▼ $106.33	$103.13B	0.58	11.50 million shs	7.69 million shs
PFE Pfizer	$26.19 +0.1%	$26.43	$23.11 ▼ $28.75	$149.15B	0.34	32.33 million shs	38.76 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GILD Gilead Sciences	-0.22%	-2.76%	-5.61%	-13.38%	+14.90%
LLY Eli Lilly and Company	-2.13%	+0.34%	+12.03%	+15.42%	+40.72%
MDT Medtronic	-0.21%	-1.90%	+5.15%	-7.98%	-8.98%
PFE Pfizer	+0.07%	+0.56%	+0.90%	-1.53%	+7.09%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GILD Gilead Sciences	$125.59 -0.2%	$133.16	$104.46 ▼ $157.29	$156.28B	0.31	7.74 million shs	5.21 million shs
LLY Eli Lilly and Company	$1,137.01 -2.1%	$998.47	$623.78 ▼ $1,182.73	$1.09T	0.53	3.12 million shs	2.43 million shs
MDT Medtronic	$80.11 -0.3%	$80.85	$73.31 ▼ $106.33	$103.13B	0.58	11.50 million shs	7.69 million shs
PFE Pfizer	$26.19 +0.1%	$26.43	$23.11 ▼ $28.75	$149.15B	0.34	32.33 million shs	38.76 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GILD Gilead Sciences	-0.22%	-2.76%	-5.61%	-13.38%	+14.90%
LLY Eli Lilly and Company	-2.13%	+0.34%	+12.03%	+15.42%	+40.72%
MDT Medtronic	-0.21%	-1.90%	+5.15%	-7.98%	-8.98%
PFE Pfizer	+0.07%	+0.56%	+0.90%	-1.53%	+7.09%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GILD Gilead Sciences	2.86	Moderate Buy	$156.93	24.95% Upside
LLY Eli Lilly and Company	2.87	Moderate Buy	$1,227.74	7.98% Upside
MDT Medtronic	2.61	Moderate Buy	$99.00	23.58% Upside
PFE Pfizer	2.25	Hold	$28.82	10.06% Upside

Current Analyst Ratings Breakdown

Latest GILD, MDT, PFE, and LLY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2026	PFE Pfizer	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underperform ➝ Sector Perform	$25.00
6/9/2026	LLY Eli Lilly and Company	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$1,330.00 ➝ $1,350.00
6/9/2026	GILD Gilead Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
6/8/2026	LLY Eli Lilly and Company	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
6/8/2026	GILD Gilead Sciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sector Perform
6/5/2026	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
6/5/2026	MDT Medtronic	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$111.00 ➝ $106.00
6/4/2026	MDT Medtronic	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$112.00 ➝ $97.00
6/4/2026	MDT Medtronic	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$90.00 ➝ $85.00
6/4/2026	MDT Medtronic	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold	$88.00
6/4/2026	MDT Medtronic	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$119.00

(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GILD Gilead Sciences	$29.44B	5.30	$10.45 per share	12.02	$18.23 per share	6.89
LLY Eli Lilly and Company	$65.18B	16.43	$24.62 per share	46.18	$28.07 per share	40.51
MDT Medtronic	$36.36B	2.83	$7.83 per share	10.23	$37.62 per share	2.13
PFE Pfizer	$62.58B	2.39	$4.40 per share	5.95	$15.26 per share	1.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GILD Gilead Sciences	$8.51B	$7.34	17.11	13.18	N/A	30.99%	48.19%	18.28%	8/6/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$28.15	40.39	25.49	1.27	34.98%	105.77%	23.76%	8/5/2026 (Estimated)
MDT Medtronic	$4.80B	$3.73	21.48	12.56	2.30	13.20%	14.61%	7.80%	8/18/2026 (Estimated)
PFE Pfizer	$7.77B	$1.31	19.99	9.16	N/A	11.83%	19.44%	8.41%	8/4/2026 (Estimated)

Latest GILD, MDT, PFE, and LLY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/3/2026	Q4 2026	MDT Medtronic	$1.54	$1.55	+$0.01	$0.96	$9.62 billion	$9.81 billion
5/7/2026	Q1 2026	GILD Gilead Sciences	$1.91	$2.03	+$0.12	$1.61	$6.91 billion	$6.96 billion
5/5/2026	Q1 2026	PFE Pfizer	$0.7220	$0.75	+$0.0280	$0.47	$13.84 billion	$14.45 billion
4/30/2026	Q1 2026	LLY Eli Lilly and Company	$6.97	$8.55	+$1.58	$8.26	$17.82 billion	$19.80 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GILD Gilead Sciences	$3.28	2.61%	+3.04%	44.69%	10 Years
LLY Eli Lilly and Company	$6.92	0.61%	+15.18%	24.58%	11 Years
MDT Medtronic	$2.84	3.55%	+4.13%	76.14%	49 Years
PFE Pfizer	$1.72	6.57%	-13.20%	131.30%	16 Years

Latest GILD, MDT, PFE, and LLY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/3/2026	MDT Medtronic	quarterly	$0.72	3.69%	6/26/2026	6/26/2026	7/17/2026
4/29/2026	GILD Gilead Sciences	quarterly	$0.82	2.45%	6/15/2026	6/15/2026	6/29/2026
4/22/2026	PFE Pfizer	quarterly	$0.43	6.71%	5/8/2026	5/8/2026	6/12/2026
5/4/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.69%	5/15/2026	5/15/2026	6/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GILD Gilead Sciences	0.89	1.97	1.77
LLY Eli Lilly and Company	1.26	1.50	1.10
MDT Medtronic	0.57	2.54	1.87
PFE Pfizer	0.67	1.25	0.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GILD Gilead Sciences	83.67%
LLY Eli Lilly and Company	82.53%
MDT Medtronic	82.06%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
GILD Gilead Sciences	0.30%
LLY Eli Lilly and Company	0.14%
MDT Medtronic	0.26%
PFE Pfizer	0.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GILD Gilead Sciences	17,000	1.24 billion	1.24 billion	Optionable
LLY Eli Lilly and Company	50,000	941.74 million	940.42 million	Optionable
MDT Medtronic	95,000	1.28 billion	1.28 billion	Optionable
PFE Pfizer	75,000	5.70 billion	5.66 billion	Optionable

GILD, MDT, PFE, and LLY Headlines

Recent News About These Companies

Pfizer Inc. $PFE Shares Bought by Victory Capital Management Inc.

4 minutes ago | marketbeat.com

State Street Corp Has $7.48 Billion Stock Position in Pfizer Inc. $PFE

45 minutes ago | marketbeat.com

Van ECK Associates Corp Sells 4,813,780 Shares of Pfizer Inc. $PFE

45 minutes ago | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 1,517,551 Shares of Pfizer Inc. $PFE

1 hour ago | marketbeat.com

Macquarie Group Ltd. Sells 628,927 Shares of Pfizer Inc. $PFE

2 hours ago | marketbeat.com

Pfizer Inc. $PFE Shares Sold by Cullen Capital Management LLC

3 hours ago | marketbeat.com

Pfizer Inc. $PFE Position Lowered by Banco Santander S.A.

4 hours ago | marketbeat.com

Allianz SE Purchases 1,750,956 Shares of Pfizer Inc. $PFE

4 hours ago | marketbeat.com

Pfizer (NYSE:PFE) Lowered to "Hold" Rating by Wall Street Zen

June 13 at 1:09 AM | americanbankingnews.com

Pfizer (NYSE:PFE) Cut to "Hold" at Wall Street Zen

June 13 at 1:08 AM | marketbeat.com

Pfizer Draws Fresh Attention As Pipeline Activity Accelerates

June 12 at 10:14 PM | kalkinemedia.comK

Pfizer Oncology Data Underscore Survival Gains And Valuation Debate

June 12 at 10:14 PM | finance.yahoo.com

What Could Push JNJ Stock Higher From Here?

June 12 at 5:13 PM | trefis.comT

Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About

June 12 at 1:10 PM | fool.com

Forget Eli Lilly and Company: As June Volatility Rocks High-Flyers, This Stock Is a No-Brainer Buy

June 12 at 10:47 AM | 247wallst.com

Pfizer Inc. $PFE Shares Bought by Xponance LLC

June 12 at 7:54 AM | marketbeat.com

Sector Gamma AS Sells 392,547 Shares of Pfizer Inc. $PFE

June 12 at 7:06 AM | marketbeat.com

Pfizer Inc. $PFE Shares Sold by Te Ahumairangi Investment Management Ltd

June 12 at 6:45 AM | marketbeat.com

Pfizer Inc. $PFE Stake Lowered by Swiss National Bank

June 12 at 6:44 AM | marketbeat.com

Pfizer Inc. $PFE Shares Sold by Logan Capital Management Inc.

June 12 at 6:01 AM | marketbeat.com

Kovack Advisors Inc. Buys 64,044 Shares of Pfizer Inc. $PFE

June 12 at 6:01 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GILD, MDT, PFE, and LLY Company Descriptions

Gilead Sciences NASDAQ:GILD

$125.59 -0.28 (-0.22%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$125.83 +0.24 (+0.19%)

As of 06/12/2026 07:59 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Eli Lilly and Company NYSE:LLY

$1,137.01 -23.94 (-2.06%)

Closing price 06/12/2026 03:59 PM Eastern

Extended Trading

$1,135.50 -1.51 (-0.13%)

As of 06/12/2026 07:59 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Medtronic NYSE:MDT

$80.11 -0.22 (-0.27%)

Closing price 06/12/2026 03:59 PM Eastern

Extended Trading

$80.22 +0.11 (+0.14%)

As of 06/12/2026 07:56 PM Eastern

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Pfizer NYSE:PFE

$26.19 +0.02 (+0.07%)

Closing price 06/12/2026 03:59 PM Eastern

Extended Trading

$26.20 +0.02 (+0.06%)

As of 06/12/2026 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GILD, MDT, PFE, and LLY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GILD, MDT, PFE, and LLY Earnings

Compare Dividends

Latest GILD, MDT, PFE, and LLY Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GILD, MDT, PFE, and LLY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GILD, MDT, PFE, and LLY Company Descriptions

Gilead Sciences NASDAQ:GILD

Eli Lilly and Company NYSE:LLY

Medtronic NYSE:MDT

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools